Forum Financial Management LP Sells 4,413 Shares of Merck & Co., Inc. $MRK

Forum Financial Management LP decreased its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 16.5% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 22,398 shares of the company's stock after selling 4,413 shares during the period. Forum Financial Management LP's holdings in Merck & Co., Inc. were worth $1,773,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Little House Capital LLC lifted its stake in Merck & Co., Inc. by 1.2% in the second quarter. Little House Capital LLC now owns 25,236 shares of the company's stock worth $1,998,000 after acquiring an additional 308 shares during the period. Semus Wealth Partners LLC lifted its stake in Merck & Co., Inc. by 8.2% in the first quarter. Semus Wealth Partners LLC now owns 5,039 shares of the company's stock worth $452,000 after acquiring an additional 382 shares during the period. Longfellow Investment Management Co. LLC lifted its stake in Merck & Co., Inc. by 20.4% in the first quarter. Longfellow Investment Management Co. LLC now owns 19,376 shares of the company's stock worth $1,739,000 after acquiring an additional 3,282 shares during the period. Quilter Plc lifted its stake in Merck & Co., Inc. by 5.6% in the first quarter. Quilter Plc now owns 1,180,797 shares of the company's stock worth $105,988,000 after acquiring an additional 62,933 shares during the period. Finally, MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH lifted its stake in Merck & Co., Inc. by 9.8% in the second quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH now owns 888,415 shares of the company's stock worth $70,327,000 after acquiring an additional 79,529 shares during the period. Institutional investors own 76.07% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Merck & Co., Inc. in a research note on Wednesday, October 8th. Berenberg Bank lowered Merck & Co., Inc. from a "buy" rating to a "hold" rating and lowered their price objective for the company from $100.00 to $90.00 in a research report on Wednesday, September 17th. Wells Fargo & Company lowered their price objective on Merck & Co., Inc. from $97.00 to $90.00 and set an "equal weight" rating for the company in a research report on Wednesday, July 30th. Citigroup initiated coverage on Merck & Co., Inc. in a research report on Monday, October 13th. They set a "neutral" rating and a $95.00 price objective for the company. Finally, Morgan Stanley lowered their price objective on Merck & Co., Inc. from $99.00 to $98.00 and set an "equal weight" rating for the company in a research report on Thursday, July 10th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $104.33.

Merck & Co., Inc. Trading Down 0.0%

Merck & Co., Inc. stock opened at $87.60 on Thursday. The business has a 50-day simple moving average of $84.28 and a two-hundred day simple moving average of $81.43. The company has a market cap of $218.81 billion, a P/E ratio of 13.50, a P/E/G ratio of 0.96 and a beta of 0.37. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $107.36. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.69.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The company reported $2.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.03 by $0.10. The business had revenue of $15.81 billion during the quarter, compared to the consensus estimate of $15.92 billion. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. Analysts predict that Merck & Co., Inc. will post 9.01 EPS for the current year.

About Merck & Co., Inc.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.